Trial Profile

A phase 3 trial of Ponesimod for the treatment of psoriasis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ponesimod (Primary)
Indications Psoriasis
Focus Registrational; Therapeutic Use

Most Recent Events

07 May 2025 According to a Vanda Pharmaceuticals media release, Investigational New Drug (IND) applications for PONVORY in the treatments of psoriasis and ulcerative colitis were accepted by the FDA in the fourth quarter of 2024.
15 May 2024 New trial record
08 May 2024 According to a Vanda Pharmaceuticals media release, company expects to initiate a Phase III study for PONVORY in the treatment of psoriasis by the end of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com